'Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdles
Publishing timestamp: 2023-10-14 13:36:09
Summary
The article discusses the challenges facing the adoption of new obesity drugs, specifically focusing on Novo Nordisk's drug Ozempic. Dr. Kavita Patel believes that while there is strong evidence supporting the drug's ability to delay progression of chronic kidney disease, data supporting its use for other conditions is underdeveloped. She also highlights barriers such as cost and adherence. Mizuho Health Care Sector Strategist Jared Holz expects challenges related to insurance coverage and questions the sustainability of the growth trend for Novo Nordisk and Eli Lilly.
Sentiment: MIXED
Keywords: weight loss surgery, weight loss diets, drug trials, stock markets, diabetes, pharmaceuticals, health insurance, weight management, prescription drugs, markets, novo nordisk a/s, obesity, medication, exercise, biotech and pharmaceuticals, investment strategy, eli lilly and co, biotechnology, breaking news: investing, health care industry, business news, breaking news: markets, wall street,
Source: https://www.cnbc.com/2023/10/14/obesity-medicine-euphoria-warning-experts-tackle-miracle-drugs.html